Literature DB >> 12091127

Methionine synthase polymorphism A2756G is associated with susceptibility for thromboembolic events and altered B vitamin/thiol metabolism.

Zoe Yates1, Mark Lucock.   

Abstract

BACKGROUND AND OBJECTIVES: Vitamin B12 dependent methionine synthase (MS) regulates de novo production of methionine from homocysteine (Hcy). Since moderate elevations in Hcy are considered vasculotoxic, we examined a common variant (A2756G-MS) of the gene coding for this enzyme as a risk for thromboembolism. DESIGN AND METHODS: We investigated A2756G-MS and folate/thiol status in 51 individuals who had experienced a thromboembolic event (TE) and 95 subjects being treated for non-thromboembolic (NTE) vascular problems.
RESULTS: The prevalence of the mutant G allele was lower in TE subjects than in controls, indicating a protective role for this base substitution (OR 0.39; 95%CI 0.20-0.78; p=0.010). Consistent with an advantage conferred by this allele, heterozygotes had generally lower levels of Hcy and glutathione (GSH), and higher levels of B-vitamins than wildtypes. The OR for the wildtype having an increased risk for TE was 2.32 (95%CI 1.06-5.08). Additionally, as might be predicted, TE-wildtypes had elevated GSH levels compared to corresponding NTE-wildtypes (p=0.004) - a likely response to oxidative stress. NTE subjects showed a dramatic reduction in Hcy between wildtype and heterozygote (p=0.017), and again between recessive and heterozygote genotypes (p=0.002). The same pattern, although not significant, occurred in TE subjects. The similarity in Hcy between clinical groups for each genotype raises questions on the etiological role of Hcy in TE. The functional relationship between enzyme variant and its B12-cofactor may be of more interest, since the polymorphic site occurs near the B12-binding domain, and our results indicate wildtype-TE subjects have a much lower level of vitamin B12 than heterozygote-TE subjects (p=0.0019). This effect is attenuated in NTE subjects. INTERPRETATION AND
CONCLUSIONS: . A2756G-MS may protect against a thromboembolic event. The role of Hcy remains unclear.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091127

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

Review 1.  Is folic acid the ultimate functional food component for disease prevention?

Authors:  Mark Lucock
Journal:  BMJ       Date:  2004-01-24

2.  Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients.

Authors:  Niveditha Muralidharan; Reena Gulati; Durga Prasanna Misra; Vir S Negi
Journal:  Clin Exp Med       Date:  2017-08-18       Impact factor: 3.984

3.  Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD).

Authors:  Jiannan Song; Kerry Ann da Costa; Leslie M Fischer; Martin Kohlmeier; Lester Kwock; Shuli Wang; Steven H Zeisel
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

4.  Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.

Authors:  David Mischoulon; Stefania Lamon-Fava; Jacob Selhub; Judith Katz; George I Papakostas; Dan V Iosifescu; Albert S Yeung; Christina M Dording; Amy H Farabaugh; Alisabet J Clain; Lee Baer; Jonathan E Alpert; Andrew A Nierenberg; Maurizio Fava
Journal:  CNS Spectr       Date:  2012-06       Impact factor: 3.790

5.  Transcobalamin-II variants, decreased vitamin B12 availability and increased risk of frailty.

Authors:  A M Matteini; J D Walston; K Bandeen-Roche; D E Arking; R H Allen; L P Fried; A Chakravarti; S P Stabler; M D Fallin
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

6.  Markers of B-vitamin deficiency and frailty in older women.

Authors:  A M Matteini; J D Walston; M D Fallin; K Bandeen-Roche; W H L Kao; R D Semba; R H Allen; J Guralnik; L P Fried; S P Stabler
Journal:  J Nutr Health Aging       Date:  2008-05       Impact factor: 4.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.